BioCentury
ARTICLE | Company News

Novo seeks approval of hemophilia A therapy

October 17, 2012 12:45 AM UTC

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) submitted regulatory applications to FDA and EMA for turoctocog alfa ( NN7008) to prevent and treat bleeding in patients with hemophilia A. Turoctocog alfa is a th...